Trial Profile
A Phase II, Multi-center, Two-Part, Three-Arm, Dose-Ranging Study of the Safety and Efficacy of Leronlimab (PRO 140) in Adult Patients With Nonalcoholic Steatohepatitis (NASH)
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 09 Mar 2023
Price :
$35
*
At a glance
- Drugs Leronlimab (Primary)
- Indications Hepatic fibrosis; Non-alcoholic steatohepatitis
- Focus Therapeutic Use
- Acronyms NASH
- Sponsors CytoDyn
- 31 Jan 2023 Status changed from active, no longer recruiting to completed.
- 08 Nov 2022 Results from open-label part2, presented at The Liver Meeting 2022: 73rd Annual Meeting of the American Association for the Study of Liver Diseases
- 08 Nov 2022 Results presented at The Liver Meeting 2022: 73rd Annual Meeting of the American Association for the Study of Liver Diseases